Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Role of the nurse immuniser in implementing and maintaining the National Human Papillomavirus ‘Cervical Cancer’ vaccine rollout through a school-based program in Victoria

Helen Kent A , Margaret E. Heffernan B F , Julie Silvers C , Elya Moore A D and Suzanne M. Garland A E D
+ Author Affiliations
- Author Affiliations

A Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Carlton, Vic. 3053, Australia.

B School of Management, RMIT University, Level 16, 239 Bourke Street, Melbourne, Vic. 3000, Australia.

C Melbourne Sexual Health Centre, 580 Swanston Street, Carlton, Vic. 3053, Australia.

D Murdoch Childrens Research Institute, University of Melbourne, Parkville, Vic. 3052, Australia.

E Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Vic. 3052, Australia.

F Corresponding author. Email: margaret.heffernan@rmit.edu.au

Sexual Health 7(3) 391-393 https://doi.org/10.1071/SH09148
Submitted: 18 December 2009  Accepted: 13 April 2010   Published: 19 August 2010

Abstract

In an effort to understand the strengths and limitations of current approaches to human papillomavirus vaccine (HPV) delivery in schools, we conducted an audit of nurse immunisers (NI). In this survey of 159 Victorian NI, the NI perceived that knowledge, safety and side effects were among the most important issues raised by parents, schoolgirls, and teachers in the school setting. The most common concern identified by NIs was the physical layout of the vaccination setting (41%), followed by safety, then knowledge of the vaccine. There is a need for ongoing assessment of factors that improve or impede the delivery of HPV vaccines.

Additional keywords: safety concerns, vaccine knowledge, vaccination setting.


References


[1] Slade BA,  Leidel L,  Vellozzi C,  Woo EJ,  Hua W,  Sutherland A, et al. Post-licensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302 750–7.
CrossRef | CAS | PubMed |

[2] Agorastos T,  Chatzigeorgiou K,  Brotherton JM,  Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009; 27 7270–81.
CrossRef | CAS | PubMed |

[3] Petousis–Harris H,  Goodyear-Smith F,  Turner N,  Soe B. Family practice nurse views on barriers to immunising children. Vaccine 2005; 23 2725–30.
CrossRef | PubMed |

[4] Nursing Board of Tasmania. Immunisation in Tasmania: Evaluation of the Nurse Immuniser Role. Hobart: Nursing Board of Tasmania; May 2006.

[5] Walboomers JMM,  Jacobs MV,  Manos MM,  Bosch FX,  Kummer JA,  Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 12–9.
CrossRef | CAS | PubMed |

[6] Garland SM,  Hernandez-Avila M,  Wheeler CM,  Perez G,  Harper DM,  Leodolter S, et al. Quadrivalent HPV6/11/16/18 vaccine to prevent cervical, vulvar and vaginal disease. N Engl J Med 2007; 356 1928–43.
CrossRef | CAS | PubMed |

[7] FUTURE II Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 1915–27.
CrossRef | PubMed |



Rent Article (via Deepdyve) Export Citation Cited By (4)